Premium
Cancer Therapy: Development of Novel Tumor‐Targeted Theranostic Nanoparticles Activated by Membrane‐Type Matrix Metalloproteinases for Combined Cancer Magnetic Resonance Imaging and Therapy (Small 3/2014)
Author(s) -
Ansari Celina,
Tikhomirov Grigory A.,
Hong Su Hyun,
Falconer Robert A.,
Loadman Paul M.,
Gill Jason H.,
Castaneda Rosalinda,
Hazard Florette K.,
Tong Ling,
Lenkov Olga D.,
Felsher Dean W.,
Rao Jianghong,
DaldrupLink Heike E.
Publication year - 2014
Publication title -
small
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.785
H-Index - 236
eISSN - 1613-6829
pISSN - 1613-6810
DOI - 10.1002/smll.201470016
Subject(s) - matrix metalloproteinase , magnetic resonance imaging , cancer research , linker , materials science , drug delivery , prodrug , cancer , targeted drug delivery , targeted therapy , medicine , nanotechnology , pharmacology , radiology , computer science , operating system
Cancer cells overexpress matrix‐type metalloproteinases (MMPs, shown as pacmen). MMPs cleave the peptide linker connecting anticancer prodrug to the dextran coated magnetic nanoparticle. After the cleavage, the drug becomes toxic (active drug shown in purple). As J. Rao, H. E. Daldrup‐Link, and co‐workers describe on page 566, this tumor specific drug release reduces the side‐effects of cancer therapy. The magnetic core of the nanoparticles allows for MRI monitoring of their distribution in the body.